[HTML][HTML] Targeting mitochondrial metabolic dysfunction in pulmonary hypertension: toward new therapeutic approaches?

M Riou, I Enache, F Sauer, AL Charles… - International journal of …, 2023 - mdpi.com
Pulmonary arterial hypertension (PAH) is a rare disease characterized by pulmonary
vascular remodeling leading to right heart failure and death. To date, despite the three …

[HTML][HTML] Mitochondrial metabolism, redox, and calcium homeostasis in pulmonary arterial hypertension

S Liang, M Yegambaram, T Wang, J Wang, SM Black… - Biomedicines, 2022 - mdpi.com
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated
pulmonary arterial pressure due to increased pulmonary vascular resistance, secondary to …

[HTML][HTML] Acquired disorders of mitochondrial metabolism and dynamics in pulmonary arterial hypertension

NM Breault, D Wu, A Dasgupta, KH Chen… - Frontiers in Cell and …, 2023 - frontiersin.org
Pulmonary arterial hypertension (PAH) is an orphan disease of the cardiopulmonary unit
that reflects an obstructive pulmonary vasculopathy and presents with hypertrophy …

[HTML][HTML] The metabolic basis of pulmonary arterial hypertension

G Sutendra, ED Michelakis - Cell metabolism, 2014 - cell.com
Pulmonary arterial hypertension (PAH) is a vascular remodeling disease of the lungs
resulting in heart failure and premature death. Although, until recently, it was thought that …

The metabolic theory of pulmonary arterial hypertension

R Paulin, ED Michelakis - Circulation research, 2014 - Am Heart Assoc
Numerous molecular abnormalities have been described in pulmonary arterial hypertension
(PAH), complicating the translation of candidate therapies to patients because, typically, 1 …

Metabolism in pulmonary hypertension

W Xu, AJ Janocha, SC Erzurum - Annual review of physiology, 2021 - annualreviews.org
Pulmonary arterial hypertension (PAH) is characterized by impaired regulation of pulmonary
hemodynamics and vascular growth. Alterations of metabolism and bioenergetics are …

Mitochondrial and metabolic drivers of pulmonary vascular endothelial dysfunction in pulmonary hypertension

Q Yu, SY Chan - Pulmonary vasculature redox signaling in health and …, 2017 - Springer
Pulmonary hypertension (PH) is a deadly and increasingly prevalent vascular disease
characterized by excessive pulmonary vascular remodeling and right ventricular dysfunction …

Mitochondrial dysfunction: metabolic drivers of pulmonary hypertension

HB Suliman, E Nozik-Grayck - Antioxidants & redox signaling, 2019 - liebertpub.com
Significance: Pulmonary hypertension (PH) is a progressive disease characterized by
pulmonary vascular remodeling and lung vasculopathy. The disease displays progressive …

Oxidative and nitrosative signalling in pulmonary arterial hypertension—Implications for development of novel therapies

T Hansen, KK Galougahi, D Celermajer… - Pharmacology & …, 2016 - Elsevier
Pulmonary arterial hypertension (PAH) is a syndrome characterised by an increase in
pulmonary vascular resistance. This results in elevated resting pulmonary artery pressure …

[HTML][HTML] Metabolism, mitochondrial dysfunction, and redox homeostasis in pulmonary hypertension

D Colon Hidalgo, H Elajaili, H Suliman, MP George… - Antioxidants, 2022 - mdpi.com
Pulmonary hypertension (PH) represents a group of disorders characterized by elevated
mean pulmonary artery (PA) pressure, progressive right ventricular failure, and often death …